[1] MOK T S, WU Y L, AHN M J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med,2017,376(7):629-640.
[2] 刘恕,李梦鹤,崔毅,等.第3代EGFR抑制剂Osimertinib Mesylate[J].药学进展,2016,40(1):74-80.
[3] GOSS G, TSAI C M, SHEPHERD F A, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2016,17(12):1643-1652.
[4] JÄNNE P A, YANG J C, KIM D W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer[J]. N Engl J Med,2015,372(18):1689-1699.
[5] SORIA J C, OHE Y, VANSTEENKISTE J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med,2018,378(2):113-125.
[6] RAMALINGAM S S, VANSTEENKISTE J, PLANCHARD D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC[J]. N Engl J Med,2020,382(1):41-50.
[7] QI W X, SUN Y J, SHEN Z, et al. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase Ⅲ clinical trials[J]. J Chemother,2015,27(1):40-51.
[8] FAN M, MO T, SHEN L, et al. Osimertinib-induced severe interstitial lung disease: A case report[J]. Thorac Cancer,2019,10(7):1657-1660.
[9] TALALUWA O, OGURI T, UEMURA T, et al. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: a case report[J]. Mol Clin Oncol, 2017,7(3):383-385.
[10] DENG S M, HUANG J A, CHEN Y B. Fatal interstitial lung disease associated with AZD9291[J]. J Cancer Res Ther, 2018, 14(Suppl): S1227-S1229.
[11] MAMESAYA N, KENMOTSU H, KATSUMATA M, et al. Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody[J]. Invest New Drugs, 2017, 35(1): 105-107.
[12] TACHI H, SHIOZAWA T, SAKAI C, et al. Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia[J]. J Thorac Oncol, 2017, 12(8): e118-e120.
[13] KIRIU T, TAMURA D, TACHIHARA M, et al. Successful Osimertinibrechallenge with steroid therapy after Osimertinib-induced interstitial lung disease[J]. Intern Med, 2018, 57(1): 91-95.
[14] MAMESAYA N, KENMOTSU H, TAKAHASHI T. Successful osimertinibrechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab[J]. Invest New Drugs, 2017,35(6):839-841.
[15] MATSUMOTO Y, KAWAGUCHI T, YAMAMOTO N, et al. Interstitial lung disease induced by Osimertinib for epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer[J]. Intern Med, 2017, 56(17): 2325-2328.
[16] SYUNYAEVA Z, BERGHOF K, KAUFFMANN G D, et al. Late-onset severe pneumonitis under osimertinib[J]. AME Case Rep, 2019, 3: 39.
[17] NIE K K, ZOU X, GENG C X, et al. AZD9291-induced Acute interstitial lung disease[J]. Chin Med J, 2016, 129(12): 1507-1508.
[18] KOMADA F. Analysis of time-to-onset of interstitial lung disease after the administration of small molecule molecularly-targeted drugs[J]. Yakugaku Zasshi, 2018, 138(2): 229-235.
[19] HIRASHIMA T, SATOUCHI M, HIDA T, et al. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: a pooled subgroup analysis[J]. Cancer Sci, 2019, 110(9): 2884-2893.
[20] WYNN T A. Integrating mechanisms of pulmonary fibrosis[J]. J Exp Med, 2011,208(7):1339-1350. |
